XM does not provide services to residents of the United States of America.
L
L

LaboratoryCorporation

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. STOCKS Newmont, Monopar Therapeutics, TKO Group

BUZZ-U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq jumped on Thursday, driven by Tesla's positive earnings forecast, which buoyed market sentiment despite declines from other corporate results and pressure from rising Treasury yields.
A
B
D
H
N
T
T
L
A
L
T
T
U
U
D
S
T
C
L
R
T

Labcorp Holdings Inc reports results for the quarter ended in September 30 - Earnings Summary

Labcorp Holdings Inc reports results for the quarter ended in September 30 - Earnings Summary Labcorp Holdings Inc LH.N reported quarterly adjusted earnings of $3.50​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $3.38. The mean expectation of seventeen analysts for the quarter was for earnings of $3.48 per share.
L

U.S. STOCKS Teck Resources, Nasdaq, T-Mobile

BUZZ-U.S. STOCKS ON THE MOVE-Teck Resources, Nasdaq, T-Mobile Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq rebounded on Thursday, after Tesla's upbeat earnings forecast lifted market sentiment following a selloff in the previous session, kicking off megacap results on a promising note.
A
B
D
H
N
T
T
L
L
T
T
U
U
D
S
T
C
L
R
T

Labcorp's quarterly results beat on diagnostic tests demand

UPDATE 1-Labcorp's quarterly results beat on diagnostic tests demand Adds analyst comment in paragraphs 5-6, changes story keyword used by media customers to LABCORP HLDG-RESULTS/ Oct 24 (Reuters) - Laboratory operator Labcorp LH.N beat Wall Street estimates for third-quarter profit and revenue on Thursday as strong demand for diagnostic tests offset a hit from hurricane-led disruptions.
L

Labcorp beats quarterly estimates on diagnostic test demand

Labcorp beats quarterly estimates on diagnostic test demand Oct 24 (Reuters) - Laboratory operator Labcorp LH.N on Thursday beat Wall Street estimates for third-quarter profit and revenue, helped by demand for diagnostic tests. Diagnostic checkups have risen in recent quarters as more people, especially older adults, caught up on surgeries deferred during the pandemic.
L

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.